Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • Offices
  • 200.Cravath

Cravath Publishes Summer 2026 Issue of Alumni Journal

Read More

News & Insights

IBM’s Acquisition of Diligent Technologies

April 18, 2008

Cravath represented IBM in its acquisition of Diligent Technologies, a privately held storage “de-duplication” technology company headquartered in Framingham, Massachusetts, with research and development located in Tel Aviv, Israel. Diligent’s technologies and employees will become part of the IBM System Storage business unit of the IBM Systems and Technology Group. The lawyers involved in the matter were partner George F. Schoen and associates Michael A. LaGatta, Raneshia L. Smith and Elissa J. Tobin on corporate matters; partner Andrew W. Needham and associate Annie Kim Choi on tax matters; partner Eric W. Hilfers and associate Daniel A. Birnhak on executive compensation and benefits matters; and associate Matthew Morreale on environmental matters. The deal was announced on April 18, 2008.

Related Practices & Industries

  • Corporate
  • Mergers and Acquisitions
  • Tax
  • Executive Compensation and Benefits
  • Technology

People

Photo
Name
Eric W. Hilfers
Title
Executive Compensation and Benefits
Title
Partner
Email
ehilfers@cravath.com
Phone
+1-212-474-1352
vCard
Download vCard

    Education

    • J.D., 1998, University of Chicago Law School
      with Honors
    • A.B., 1995, Princeton University

    Admitted In

    • New York
    Photo
    Name
    Andrew W. Needham
    Title
    Tax
    Title
    Retired Partner
    Email
    aneedham@cravath.com
    Phone
    +1-212-474-1999
    vCard
    Download vCard

      Education

      • M.B.A., 1992, The Wharton School of the University of Pennsylvania
      • LL.M., 1990, Georgetown University Law Center
      • J.D., 1986, Georgetown University Law Center
      • B.A., 1982, University of Arizona College of Law
      Photo
      Name
      Matthew Morreale
      Title
      Corporate
      Title
      Retired Partner
      Email
      mmorreale@cravath.com
      Phone
      +1-212-474-1534
      vCard
      Download vCard

        Education

        • J.D., 1997, Columbia Law School
          Harlan Fiske Stone Scholar
        • M.S., 1994, University of Pennsylvania
        • B.A., 1990, University of Pennsylvania
        • B.A.S., 1990, University of Pennsylvania

        Related News & Insights

        Deals & Cases

        November 05, 2026

        Liberty Media’s Acquisition of High‑Vote Series B Common Stock from John C. Malone‑Related Entities

        On November 5, 2026, Liberty Media Corporation (“Liberty Media”) announced that it has acquired all shares of Liberty Media’s high‑vote Series B common stock held by certain entities related to John C. Malone (the “Malone Holders”) in exchange for shares of Liberty Media’s low‑vote Series A common stock and shares of Liberty Media’s non‑voting Series C common stock. As a result of the transaction, the Malone Holders’ aggregate voting power in Liberty Media declined to approximately 3%, and no holder of Liberty Media common stock holds more than 9% of Liberty Media’s voting power, in each case, based on Liberty Media’s outstanding common stock as of October 30, 2026. The transaction was negotiated and approved by a special committee (the “Special Committee”) of Liberty Media’s board of directors consisting solely of disinterested and independent directors for purposes of Nevada law, advised by its own independent financial and legal advisors. Cravath is representing the Special Committee in connection with the transaction.

        Deals & Cases

        October 29, 2026

        ADT’s $15.3 Billion Acquisition by Thrive Holdings

        On October 29, 2026, ADT Inc. (“ADT”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, announced a definitive agreement under which Thrive Holdings will acquire ADT in an all‑cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange. Cravath is representing ADT in connection with the transaction.

        Deals & Cases

        August 31, 2026

        Aon’s $17 Billion Acquisition of USI

        On August 31, 2026, Aon, a leading global professional services firm, announced the signing of a definitive agreement to acquire USI, a leading provider of property & casualty, employee benefit, personal risk and retirement solutions for the middle market and the tenth largest U.S. insurance broker, from KKR and other shareholders for a total purchase price of $17 billion. Aon expects to fund the transaction, as well as related transaction expenses and other costs, with new debt raised across a range of maturities, subject to market conditions. The transaction has been unanimously approved by the Board of Directors of Aon and the Board of Directors of USI. Cravath is representing Aon in connection with the transaction.

        Deals & Cases

        March 31, 2026

        Biogen’s $5.6 Billion Acquisition of Apellis

        On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.

        Cravath Bicentennial

        Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

        Explore

        Cravath, Swaine & Moore LLP Logo
        • CONTACT US
        • OUR STORY
        • ALUMNI PORTAL
        • DISCLAIMERS & NOTICES

        Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.